Clinical Trial

Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma

Study acronym: ARIADNE
Recruiting
View on ClinicalTrials.gov →
Summary
The objective of this NIS is to evaluate medical resource utilization, where data is rare in all cohorts, patient's QoL and effectiveness of zanubrutinib treatment in adult patients with WM, CLL, MZL and FL in a real-world setting.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-04-05; most recent amendment 2025-09-18.
Status change: Not Yet Recruiting → Recruiting 2022-05-02
Trial Details
NCT Number NCT05326308
Lead Sponsor iOMEDICO AG
Collaborators: BeOne Medicines I GmbH Switzerland
Conditions Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma, Follicular Lymphoma
Enrollment 705 participants
Start Date 2022-04-26
Primary Completion 2028-08 (estimated)
Study Completion 2028-08 (estimated)
Updated on ClinicalTrials.gov 2025-09-23